RxDoctor Payments Data

Kathryn Beldowski, MD

Geriatric Medicine · Broomall, PANPI 1487947487

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.9% of the total across 178 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 12.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,096 and has fallen 67.5% since, to $356 in 2025. Among geriatric medicine clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,613in general payments, 2019–2025

Across 178 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$464
  • Novo Nordisk$331
  • Teva Pharmaceuticals USA, Inc.$293
  • Otsuka America Pharmaceutical, Inc.$287
  • Novartis$232
  • GSK$213
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,608100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,613 in reported general payments places this provider in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.

See all geriatric medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$88,370
Medicare patients
347
Services billed
1,343

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban283$121,940
JardianceEmpagliflozin130$71,395
OzempicSemaglutide58$69,266
TrulicityDulaglutide49$52,701
XareltoRivaroxaban110$44,844
JanuviaSitagliptin Phosphate87$44,574
MounjaroTirzepatide25$28,495
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$26,070
NuplazidPimavanserin Tartrate11$25,893
MyrbetriqMirabegron102$23,867
AbrysvoRsv Vacc, Pref A And Pref B/Pf68$21,501
Nurtec OdtRimegepant Sulfate19$20,154
LinzessLinaclotide32$18,376
Atorvastatin Calcium877$13,983
Paliperidone ErPaliperidone21$13,845

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo, Nurtec Odt$99$163,595370 claims
Lilly USA, LLCTrulicity, Mounjaro, Olanzapine$464$87,509209 claims
Boehringer IngelheimJardiance$15$71,395130 claims
Novo NordiskOzempic$331$69,26658 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$213$46,08182 claims
Johnson & JohnsonXarelto$173$44,844110 claims
Acadia Pharmaceuticals IncNuplazid$109$25,89311 claims
Astellas Pharma US IncMyrbetriq$20$23,867102 claims
AbbVieLinzess, Restasis$115$23,67243 claims
AstraZenecaFarxiga, Lokelma$68$20,57270 claims
NovartisEntresto$232$13,72646 claims
Sumitomo Pharma America, Inc.Gemtesa$139$10,84429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 217 geriatric medicine providers in Pennsylvania.

Other geriatric medicine in Broomall

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →